SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
Rhea-AI Summary
SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.
The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.
The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.
Positive
- Record Q1 revenue of $9.1-9.3 million, up 57-61% year-over-year
- UltraMIST revenue grew 65% compared to Q1 2024
- Performance exceeded upper end of previous guidance
- Domestic manufacturing shields from tariff impacts
Negative
- Heavy revenue concentration (99%) in single product line UltraMIST
- Recent sales force restructuring and leadership changes indicate organizational flux
Insights
SANUWAVE Health's preliminary Q1 2025 revenue of
The revenue exceeding the upper end of management's previous guidance demonstrates strong execution and suggests the company may be gaining momentum in the wound care market. Their flagship product, UltraMIST, drove this performance with
While the strong growth trajectory is encouraging, the extreme concentration in a single product line presents a potential vulnerability. Having essentially all revenue tied to UltraMIST creates significant risk if any competitive, regulatory, or production challenges emerge for this product specifically.
The domestic manufacturing disclosure is strategically timed amid investor concerns about tariffs and international supply chain disruptions. This insulates SANUWAVE from current trade tensions and provides operational stability that many medical device competitors with international manufacturing might not enjoy.
Management's characterization of 2025 as a "breakout year" and reference to a "robust pipeline" signals confidence in sustaining this growth trajectory, though investors should watch for more concrete evidence in future quarters to confirm this optimism is warranted.
SANUWAVE is pleased to announce preliminary revenues of
Q1 2025 revenue increased between
UltraMIST revenues for Q1 2025 increased by more than
EDEN PRAIRIE, Minn., April 08, 2025 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2025 are expected to be in the range of
“Sanuwave is pleased to announce a strong start to 2025, putting up our best Q1 in Company history,” said CEO Morgan Frank. “Q1 was a transition quarter as we moved to a new head of sales and restructured the sales force. I’m very proud of the team managing this without missing a beat. Our pipeline remains robust and consistent with 2025 being a breakout year for Sanuwave. The Company plans to release its full Q1 results on or around May 9, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
“Given the current trade climate and as we have received a number of questions from investors, I’d also like to take this opportunity to clarify that all manufacturing for the UltraMIST system and its applicators is performed domestically. Sanuwave does not anticipate any significant effects on production from the current tariff situation.”
The preliminary revenue results described herein are based on management’s initial analysis of the first quarter ended March 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
What were SANUWAVE's (SNWV) Q1 2025 revenue numbers?
How much did SANUWAVE's UltraMIST revenue grow in Q1 2025?
When will SANUWAVE release full Q1 2025 financial results?
Is SANUWAVE affected by current tariff situations?
Did SANUWAVE meet its revenue guidance for Q1 2025?
